Bionano Genomics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Bionano Genomics generated cash of -$125,181,000, which is less than the previous year. Cash used in financing activities reached the amount of $113,815,000 last year. Net change in cash is therefore $12,857,000.
Cash Flow
| 2016 | -23.49M | -1.34M | 25.43M |
|---|---|---|---|
| 2017 | -20.81M | -1.01M | 17.60M |
| 2018 | -19.94M | -331.71K | 35.77M |
| 2019 | -29.52M | -61.05K | 30.37M |
| 2020 | -38.31M | -2.44M | 61.90M |
| 2021 | -71.92M | -278.06M | 336.11M |
| 2022 | -124.81M | 82.76M | 23.00M |
| 2023 | -125.18M | 24.15M | 113.81M |
BNGO Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 5.49M | 24.57M | 38.44M | 17.31M | 16.52M | 1.02M | 5.24M | 4.66M |
Operating activities | ||||||||
Net income | -232.49M | -132.59M | -72.43M | -41.10M | -29.81M | -18.49M | -23.36M | -18.84M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 13.91M | 9.84M | 3.37M | 1.47M | 1.12M | 1.32M | 1.50M | 1.11M |
Stock-based compensation expense | 15.17M | 22.41M | 9.71M | 1.55M | 1.34M | 0 | 382.83K | 130.64K |
| Deferred income tax benefit | 15.17M | 22.41M | 9.71M | 1.55M | 1.34M | 0 | 382.83K | 130.64K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | -2.29M | -2.9M | -493K | 2.08M | -2.37M | -900.11K | -1.76M | -856.09K |
Inventories | -4.15M | -23.67M | -15.92M | -4.20M | -3.64M | -418.98K | -336.04K | -726.13K |
Accounts payable | -1.99M | 1.94M | 6.78M | -1.80M | 1.36M | -954.37K | 1.54M | -608.65K |
Cash generated by operating activities | -125.18M | -124.81M | -71.92M | -38.31M | -29.52M | -19.94M | -20.81M | -23.49M |
Investing activities | ||||||||
Purchases Of Investments | -111.26M | -84.19M | -313.39M | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -1.69M | -3.30M | -1.46M | 0 | -61.05K | -331.71K | -1.01M | -1.34M |
Acquisitions Net | 96K | -31.34M | -49.08M | -2.44M | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 24.15M | 82.76M | -278.06M | -2.44M | -61.05K | -331.71K | -1.01M | -1.34M |
Financing activities | ||||||||
Common Stock Issued | 57.69M | 23.12M | 342.71M | 39.93M | 19.55M | 19.38M | 17.60M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -2M | 0 | 0 | 0 | 0 |
Repayments of term debt | -47K | -36K | -15.00M | -7.25M | 9.82M | -7.44M | 0 | -5M |
Cash used in financing activities | 113.81M | 23.00M | 336.11M | 61.90M | 30.37M | 35.77M | 17.60M | 25.43M |
Net Change In Cash | 12.85M | -19.08M | -13.87M | 21.13M | 788.64K | 15.50M | -4.22M | 584.85K |
Cash at end of period | 18.34M | 5.49M | 24.57M | 38.44M | 17.31M | 16.52M | 1.02M | 5.24M |
| Data source | Data source | Data source | Data source | Data source | Data source |